Drug trial aims to tame dangerous metabolism in rare fat disorder
NCT ID NCT05088460
Summary
This study tested an experimental drug called REGN4461 to see if it could help control serious metabolic problems in people with a rare genetic condition called familial partial lipodystrophy. The condition causes abnormal fat distribution and often leads to dangerously high blood sugar and fat levels. The trial was small, enrolling 20 participants, and was designed to measure changes in these levels, liver fat, and feelings of hunger over 12 to 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL PARTIAL LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complexo Hospitalario Universitario de Santiago-Hospital Médico-Cirúrxico de Conxo
Santiago de Compostela, Galicia, 15706, Spain
-
Ege University Faculty of Medicine
Izmir, Bornova, 35100, Turkey (Türkiye)
-
Excel Medical Clinical Trials - A Flourish Research Site
Boca Raton, Florida, 33434, United States
-
ICAN, Institute of Cardiometabolism and Nutrition
Paris, 75013, France
-
National Institute of Health
Bethesda, Maryland, 20892, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.